Tumor-producing Myc protein can be targeted at last

Share this article:

The surprising discovery of an important functional link between the Myc oncogene and a regulator of protein synthesis control has finally provided scientists with a way to attack Myc-driven hematologic cancers.

Myc is one of the most commonly deregulated oncogenes in human cancer, acting somewhat as a master switch within cells to foster their uncontrolled growth. This tumor-driving protein has been previously impossible to target with drugs.

Now, however, a team led by Davide Ruggero, PhD, and Kevan Shokat, PhD, both of the University of California–San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center (San Francisco, California), has uncovered a biochemical link between Myc and mammalian target of rapamycin (mTOR)–dependent phosphorylation of a protein known as 4EBP1. 4EPP1 is a master regulator of protein production, and not only does Myc drive protein production, but Myc-driven cancer cells become dependent on this ability to make abnormal amounts of protein. When present in tumors, both abnormal Myc and abnormal mTOR are known to be able to “rev up” protein production and foster cell growth, according to a statement from UCSF.

As the researchers recounted in Proceedings of the National Academy of Sciences of the United States of America (PNAS), mTOR-dependent phosphorylation of 4EBP1 is required for cancer cell survival in Myc-dependent tumor initiation and maintenance. They further learned that an mTOR inhibitor capable of blocking 4EBP1 phosphorylation has remarkable therapeutic efficacy in Myc-driven hematologic cancers: The experimental drug, called MLN0128, stopped tumor growth in mouse models of Myc-driven lymphoma and multiple myeloma. (Currently available mTOR inhibitors do not inhibit mTOR's ability to target 4EBP1, noted the UCSF statement.)

“This is a unique therapeutic approach to make MYC ‘druggable' in the clinic,” Shokat commented in the UCSF statement.

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Postmenopausal breast cancer risk drops off after starting regular physical activity

Postmenopausal women who in the past 4 years had undertaken regular physical activity equivalent to at least 4 hours of walking per week had a lower risk for invasive breast cancer compared with women who exercised less

Mutations in the PALB2 gene increases risk of breast cancer by age ...

The PALB2 gene is potentially one of the most important genes associated with breast cancer after the BRCA1/2 genes.

Existing drug offers new hope in a subtype of pancreatic cancer

A new use for an old drug shrinks a particular type of pancreatic cancer and stops it from spreading, according to new research.